New drug combo targets tough ovarian cancer in early trial
Disease control
Recruiting now
This early-phase study tests a new drug called DT2216 combined with the chemotherapy paclitaxel in people whose ovarian cancer has returned and is resistant to platinum-based treatments. The main goal is to find the highest safe dose of DT2216 when given with paclitaxel. About 30…
Phase: PHASE1 • Sponsor: Elizabeth Stover, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC